Evoke Pharma Welcomes Ben Smeal to the Board of Directors

Author: Caleb Price Updated: 10-22-2024 08:46 AM

New Leadership at Evoke Pharma with Ben Smeal Joining the Board

Evoke Pharma, Inc. (NASDAQ: EVOK), a prominent specialty pharmaceutical firm, has added Ben Smeal to its Board of Directors. This strategic appointment comes as a response to an obligation related to recent financing efforts by Nantahala Capital Management.

The Journey and Experience of Ben Smeal

With an impressive background in corporate governance and investment management, Mr. Smeal brings a wealth of experience. Prior to his focus on private investment, he contributed his expertise at Willett Advisors, which is associated with Michael R. Bloomberg, and Kenmare Management, a well-respected hedge fund. These roles have equipped him with an understanding of strategic business development and equity investments.

Marketing Expertise and Diverse Background

Additionally, Mr. Smeal's tenure as Marketing Director at Overstock.com allowed him to develop significant skills in traditional and digital marketing. This experience enhances his capability to foster growth and encourage innovative strategies within Evoke Pharma.

CEO Matt D'Onofrio's Statement

“We are thrilled to welcome Ben to our board,” shared Matt D'Onofrio, CEO. His deep knowledge in public equities and corporate leadership promises to drive forward the mission of making GIMOTI more accessible to patients in need.

Ben Smeal's Enthusiastic Response

In his own words, Ben expressed excitement about joining Evoke’s Board of Directors: “I am honored to join Evoke’s Board of Directors. The company’s unwavering dedication to improving patient outcomes in such an underserved area of medicine resonates deeply with me, and I look forward to working with the team to drive future success.”

About Evoke Pharma, Inc.

Evoke Pharma focuses on developing innovative medicines aimed at treating gastrointestinal (GI) disorders. Their flagship product, GIMOTI, is a nasal spray formulation designed to relieve symptoms of diabetic gastroparesis, a condition impacting many adults globally.

The Impact of Diabetic Gastroparesis

This condition poses significant challenges as it delays gastric emptying, leading to severe gastrointestinal symptoms and complicating the absorption of oral medications. Before GIMOTI's FDA approval, metoclopramide was only available in oral and injectable forms, making GIMOTI the sole drug currently approved to treat gastroparesis in the United States.

Accessing More Information

For further details about Evoke and their innovative products, visit their website at www.EvokePharma.com.

Frequently Asked Questions

1. What is Evoke Pharma's primary focus?

Evoke Pharma specializes in developing treatments for gastrointestinal disorders, particularly diabetic gastroparesis.

2. Who is Ben Smeal?

Ben Smeal is the newly appointed member of Evoke Pharma's Board of Directors, bringing extensive investment management and marketing experience.

3. What is GIMOTI?

GIMOTI is a nasal spray formulation of metoclopramide approved for the treatment of diabetic gastroparesis symptoms.

4. Why is the appointment of Ben Smeal significant?

His experience in corporate governance and marketing is expected to enhance Evoke Pharma's strategic direction and growth.

5. How can I learn more about Evoke Pharma?

For in-depth information about their products and updates, you can visit www.EvokePharma.com.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.